Drug Profile

Barzolvolimab - Celldex Therapeutics Inc

Alternative Names: Anti-KIT monoclonal antibody - Celldex Therapeutics; CDX-0159

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Toronto; Yale University School of Medicine
Developer Celldex Therapeutics Inc
Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
Mechanism of Action Proto-oncogene protein c-kit inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Chronic urticaria
Phase II Atopic dermatitis; Eosinophilic oesophagitis; Prurigo nodularis

Most Recent Events

28 Aug 2025 No recent reports of development identified for phase-I development in Eosinophilic-oesophagitis in USA (IV)
20 Aug 2025 Phase-III clinical trials in Chronic-urticaria (Treatment-experienced) in Croatia, Mexico, Tunisia (SC) (NCT06455202)
19 Aug 2025 Updated efficacy and adverse event data from the phase II EvolvE trial in eosinophilic esophagitis released by Celldex Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com